In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec, as an oral therapy for patients with chronic myeloid leukemia, or CML.
Mar 9, 2017
0
2
A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs)—soft tissue tumors that are stubbornly resistant to chemotherapy and radiation—according to a laboratory study ...
Jan 31, 2024
0
59
(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according ...
May 23, 2012
0
0
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal ...
Jun 1, 2012
0
0
A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.
May 17, 2017
0
1
Researchers at University of California, San Diego School of Medicine have determined that certain gastrointestinal stromal tumors (GISTs) are more deadly than previously reported in medical literature. Findings are published ...
Apr 5, 2016
0
1
A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium ...
Apr 7, 2013
0
0
University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.
Feb 13, 2014
0
0
Researchers from the University of Colorado Anschutz Medical Campus have identified a new feature indicative of the chance of recurrence of Gastrointestinal Stromal Tumors (GISTs).
Jan 10, 2023
0
2
Nine years ago, SWOG researchers confirmed a new standard of care for patients with incurable gastrointestinal stromal tumors (GIST), who could survive by being treated with imatinib mesylate, the breakthrough drug marketed ...
Feb 20, 2017
0
1
